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Adult-onset autosomal dominant leukodystrophy (ADLD) is a progressive and fatal hereditary demyelination
disorder characterized initially by autonomic dysfunction and loss of myelin in the central nervous system (CNS).
Majority of ADLD is caused by a genomic duplication of the nuclear lamin B1 gene (LMNB1) encoding lamin B1
protein, resulting in increased gene dosage in brain tissue. In vitro, excessive lamin B1 at the cellular level reduces
transcription of myelin genes, leading to premature arrest of oligodendrocyte differentiation. Murine models of
ADLD overexpressing LMNB1 exhibited age-dependent motor deficits and myelin defects, which are associated with
reduced occupancy of the Yin Yang 1 transcription factor at the promoter region of the proteolipid protein gene.
Lamin B1 overexpression mediates oligodendrocyte cell-autonomous neuropathology in ADLD and suggests lamin
B1 as an important regulator of myelin formation and maintenance during aging. Identification of microRNA-23
(miR-23) as a negative regulator of lamin B1 can ameliorate the consequences of excessive lamin B1 at the cellular
level. miR-23a-overexpressing mice display enhanced oligodendrocyte differentiation and myelin synthesis. miR-23a
targets include a protein coding transcript PTEN (phosphatase and tensin homolog on chromosome 10), and a long
noncoding RNA (2700046G09Rik), indicating a unique role for miR-23a in the coordination of proteins and
noncoding RNAs in generating and maintaining healthy myelin. Here, we provide a concise review of the current
literature on clinical presentations of ADLD and how lamin B1 affects myelination and other developmental
processes. Moreover, we address the emerging role of non-coding RNAs (ncRNAs) in modulating gene networks,
specifically investigating miR-23 as a potential target for the treatment of ADLD and other demyelinating disorders.
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Compact concentric wraps of myelin, a unique charac-
teristic of vertebrates, can speed up propagation of elec-
trical activities along axons in the nervous system.
Myelin sheath consists of membranous outgrowth from
specified glia such as oligodendrocytes in the central
nervous system (CNS) and Schwann cells in the periph-
eral nervous system. In adults, oligodendrocytes are gen-
erated by proliferation or migration of oligodendrocyte
progenitors cells (OPC) throughout the CNS, followed
by differentiation into post-mitotic pre-myelinating oli-
godendrocytes and myelination of adjacent axons when* Correspondence: ying-hui.fu@ucsf.edu
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stated.appropriate environmental cues are present [1-6]. Mo-
lecular mechanisms underlying oligodendrocyte differen-
tiation and CNS myelination include intrinsic cues such
as transcriptional factors, microRNAs (miRNAs), and
chromatin remodeling, and extrinsic signaling such as
extracellular ligands and neuronal activities [1]. A num-
ber of transcription factors have been identified that pro-
mote oligodendrocyte specification [7,8], differentiation,
myelination [7-13], or prevent OPC from differentiating
[14-17]. Failure to integrate these molecular mechanisms
may lead to myelin malformation or premature break-
down of myelin similar to that observed in human diseases
such as hereditary leukodystrophies or multiple sclerosis. In
this review, we address adult onset autosomal dominant
leukodystrophy (ADLD), recently shown to be caused by
increased expression of lamin B1 resulting from duplication. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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sibly its dysregulation [25]. Importantly, the adverse effect
of LMNB1 overexpression in oligodendrocytes can be ab-
rogated by miR-23, suggesting that it may be a negative
regulator of lamin B1 [26]. Therefore, we will discuss the
clinical presentation of ADLD, and how lamin B1 affects
myelination (both when in excess and in its absence).
Moreover, we discuss the emerging role of non-coding
RNAs (ncRNAs) in modulating gene networks, specifically
investigating miR-23 as a potential target for the treatment
of ADLD and other demyelinating disorders.
Clinical presentation of adult-onset autosomal
dominant leukodystrophy
ADLD was originally reported for a large American-Irish
family carrying a progressive and fatal neurological white
matter disorder [27]. Additional ADLD families were sub-
sequently found in other ethnic groups [19,28-33]. Typical
ADLD symptoms begin between the forth and sixth de-
cades of life with early presentation of autonomic symp-
toms, including bowel/bladder dysfunction, impotence
in males, and orthostatic hypotension [34-36]. Recent evi-
dence of delayed onset of autonomic dysfunction in a
Serbian family with LMNB1-dupication presents a variant
of the ADLD symptoms [31]. Clinically, it is a progressive
degenerative neurological disorder characterized by pyram-
idal, cerebellar, and autonomic abnormalities [27,29,30,37].
Autonomic symptoms are followed by cerebellar impair-
ment (ataxia, dysmetria, nystagmus, and action tremors)
and pyramidal abnormalities (spasticity and weakness of
both upper and lower extremities). Cardiovascular and
pharmacological assessments indicate a selective sympa-
thetic failure with spared cardiovagal response [36,38].
Mild cognitive, visual, and auditory abnormalities are also
found in some cases. Selective loss of noradrenergic fibers
with preserved cholinergic fibers in skin biopsy of a pa-
tient with ADLD [36] indicates autonomic neuropathy.
However, peripheral nerve, sympathetic ganglia, vagus
nerve, and adrenal medulla did not exhibit obvious abnor-
mality at autopsy [38]. The MRI scans display diffused,
confluent and symmetric white matter degeneration start-
ing in the frontoparietal region, extending towards the
brainstem and cerebellar white matter [30,35,39]. Periven-
tricular white matter appears less involved than the
adjacent white matter [30]. The diameter of the medulla
oblongata is reduced in the coronal plane and the corpus
callosum is also atrophic. White matter changes are most
significant in the brain though spinal cord involvement
has been reported in some cases [40]. Neuropathological
findings reveal white matter abnormalities in the fronto-
parietal and cerebellar white matter but spare the cortex
and subcortical U fiber in symptomatic ADLD patients
[30,35]. Light microscopy showed vacuolated white matter
with no significant loss of oligodendroglia, which has noclear sign of inflammatory changes and reactive astrocy-
tosis [30,35]. In addition, sparse astrocytes with intense
immunoreactivities against insulin-like growth factor-1
and vimentin are accompanied by beaded/foreshortened
morphology or thickening processes. Reduced numbers of
Purkinje cells and slightly increased numbers of Bergmann
cells in cerebellum are also found [30]. Lacking signifi-
cant inflammatory infiltrates, activated microglia, or mac-
rophages, this disorder does not appear to result from the
direct autoimmune attack on myelin proteins that is present
in multiple sclerosis. Overall, preservation of oligodendro-
glia in the presence of demyelination and the lack of or
moderate astrogliosis under light microscopy are the
unique features of ADLD [30,35]. Genetic evidence dem-
onstrates that ADLD is caused by duplication of LMNB1
in the majority of ADLD patients [18-24], and recent
study from twenty families revealed a minimal 72 kb of
LMNB1 duplication required for the disease [23]. How-
ever, how this mutation leads to these described cellular
phenotypes is not completely clear. Therefore, in the next
section we survey current research on lamin B1 and how
over- or under-expression of this protein can dysregulate
myelination.
Lamin B1 is integral to the nuclear lamina
and regulates gene expression
Lamins are structural components of the nuclear lamina,
which is a filamentous meshwork of proteins underlying
the inner nuclear membrane. Nuclear lamina has been
found to play dynamic roles in the organization and
regulation of chromatin, transcription, DNA replication,
DNA repair, and various epigenetic phenomena such as
euchromatin and heterochromatin transitions [41]. RNA
interference-mediated knocking down of the only lamin,
Ce-lamin, in C. elegans leads to embryonic lethality due
to defects in cell cycle progression, chromosome segre-
gation, chromatin organization and correct spacing of
nuclear pore complexes [42]. Similarly, depletion of the
B-type lamin, lamin Dm0, in Drosophila cultured cells
and embryos by RNA interference results in morpho-
logical alterations of nuclei, nuclear fragility and the arrest
of embryonic development [43]. Mammalian cells have
two major types of lamins, A-type and B-type, and muta-
tions in genes encoding the nuclear lamins can cause a
wide range of human diseases, collectively called lamino-
pathies (for review, see [44-47]). B-type lamins include
lamin B1 encoded by LMNB1 (mouse Lmnb1) and lamin
B2 encoded by LMNB2 (mouse Lmnb2). Lamins anchor
chromatin to the nuclear lamina and act as a scaffold for
chromatin remodeling, and are thus critical for determin-
ing spatial organization of chromosomes in the nucleus
[48]. Furthermore, genomic regions tethered to the nu-
clear periphery were shown to be associated with reduced
transcription of genes in the region, suggesting that lamins
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[49,50]. Cells isolated from human with laminopathies or
murine models with lamin deficiency all displayed abnor-
mal nuclear structures [51-53]. Numerous diseases are as-
sociated with LMNA mutations, with symptoms ranging
from myopathy, lipodystrophy, accelerated aging disor-
ders, peripheral neuropathy, to bone disorders [46,54]. Re-
cent studies in murine models of Lmna mutations suggest
that mutations in the A-type lamin confer phenotypes by
gain-of-function toxicity for some models and loss-of-
function for others [46]. In contrast, myelin disease is the
only reported phenotype associated with LMNB1 duplica-
tions [18] while acquired partial lipodystrophy is associ-
ated with mutations in LMNB2 [55]. Lamin B1 has been
reported to play a role in cell proliferation and senescence
in culture [56-58], and both silencing and overexpressing
lamin B1 have been linked to senescence [56,57,59]. How-
ever, the B-type lamins do not affect the development of
skin keratinocytes and hepatocytes [60,61], which appear
morphologically normal in histological analyses. Given
that lamin B1 binds to genes whose expression are not
essential for proliferation and survival or in vitro lineage
specification in embryonic stem cells [62], we propose that
lamin A and lamin B1 control different sets of gene ex-
pression through direct chromatin-binding, and that B-
type lamins may specifically affect neural development,
whereas A-type lamins may preferentially affect other cell
types. During differentiation, differences in temporal and
spatial expression of A-type and B-type lamins will result
in different chromatin patterns, thus conferring unique
transcriptome signatures of cell lineage.
Lamin B1 is necessary for proper cellular
development
Consistent with its proposed role in regulating specific
gene expression, lamina-associated domains of lamin B1
are connected to genome regions with low expression
levels, exhibiting lower levels of active chromatin, and
enriched with silenced chromatin markers that indicate re-
pressive chromatin organization [62-65]. The high-resolution
genome-nuclear lamina interaction maps of lamin B1 in
pluripotent embryonic stem cells, multipotent precursor
cells, and terminal differentiated cells revealed a dynamic
interaction of nuclear lamina and genes in the genome ac-
cording to cell type, differentiation steps, and gene expres-
sion levels that correlate with subsequent repression or
activation [66]. These unique characteristics of lamin B1
suggest its importance in cellular development that re-
quires temporal and spatial regulation of gene networks.
Supporting this hypothesis, Drosophila testis’ nuclear
lamin-B regulates cyst stem cell differentiation and organization
of the niche through nuclear epidermal growth factor re-
ceptor signaling [67]. Furthermore, deficiencies of lamin
B1 and/or lamin B2 in mice lead to perinatal lethality,especially due to poor lung development [51,62,68,69].
Knockout of Lmnb1/2 or Lmnb1 alone also results in
microcephaly. Despite developmental impairment, lamin
B2 deficiency has comparatively better-developed lung,
brain, and diaphragm, suggesting a possible functional
redundancy between the B-type lamins [62,68]. In recent
years, lamin B1 and lamin B2 have been demonstrated to
play a critical role in neuronal migration in mouse cerebral
cortex and cerebellum [52,62,68]. Impairment of neuronal
migration in cortex was attributed to improper connection
between cytoskeleton and the nucleus [62], which is con-
sistent with increased nuclear spinning (an indication for
impairment in anchoring the nucleus to cytoskeleton) in
fibroblasts cultured from Lmnb1Δ/Δ mice [70]. Similarly,
spindle orientation defects have been identified in cerebral
cortex in Lmnb1 knockout mice that lead to defects in div-
ision of neural progenitor cells [71]. In addition, acceler-
ated cell cycle exit and enhanced apoptosis in cerebral
cortex of Lmnb1 knockout mice suggest that lamin B1
may also modulate proliferation potential and differenti-
ation of neural progenitor cells and neurons in the embry-
onic brain [62].
The mammalian lamin B1 is post-translationally modified
by farnesylation, endoproteolysis, and carboxymethylation
at a carboxyl-terminal CaaX motif [72], and its specific
interacting portions appear to be important for its func-
tion. For example, gene trap insertion in mouse resulting
in an allele encoding lamin B1 lacking the C terminus
causes perinatal lethality due to lung and bone abnormal-
ities [51]. Furthermore, impaired farnesylation of lamin B1
leads to loss of chromatin anchor to the nuclear lamina,
and causes migratory defects of neurons in brains and
perinatal lethality [73]. Together, these results suggest that
developmental processes are highly sensitive to both the
expression level and post-translational modifications of
lamin B1. Interestingly, lamin B1 itself in the brain is de-
velopmentally regulated, with levels peaking at birth or
postnatal day 1, followed by a gradual decrease from post-
natal day 1 to 10 months of age [26] whereas levels of
many myelin proteins in the murine brain gradually in-
crease with age in a pattern that is complementary to that
of lamin B1. These results imply a possible role for lamin
B1 in the regulation of oligodendrocyte development or
myelin proteins expression.
Lamin B1 overexpression leads to demyelination
Overexpression of the B-type lamins was previously shown
to promote nuclear membrane growth and intranuclear
membrane formation in amphibian oocytes, epithelium,
and mammalian kidney cells in a CaaX motif-dependent
manner [74,75]. In agreement with these findings, ectopic
overexpression of lamin B1 in neural and glial cell lines in-
crease surface area of nuclear membrane and intranuclear
aggregates [26]. Increased expression of lamin B1 also
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proteins, chromatin organization, and nuclear pore trans-
port. It is possible that formation of abnormal intranuclear
membranes caused by excessive lamin B1 production leads
to the altered subcellular localization of nuclear envelope
proteins and perturbed nuclear transport, especially in
oligodendrocytes. Supporting this hypothesis, widespread
overexpression of lamin B1 in mouse brain using bacterial
artificial chromosome (BAC) transgenic engineering reca-
pitulates many of the clinical features present in ADLD,
including aberrant myelin formation, axonal degener-
ation and demyelination [76]. LMNB1BAC mice exhibit
seizure, cognitive impairment, and motor deficits, which
progressively worsen with age. Remarkably, lineage-specific
overexpression of lamin B1 in mouse oligodendroglia is
sufficient for reproducing the histopathological, molecular
and behavioral abnormalities in ADLD. Although de-
creased abundance of myelin protein, proteolipid protein
(PLP), attributed to loss of occupancy of a transcription
activator, Yin Yang 1 (YY1) on its promoter, contributes at
least in part to the myelin phenotype in ADLD, the possi-
bility that an independent degenerative process of myelin
also contributes to the phenotype has not been excluded.
Nevertheless, these results suggest that genes required for
myelin proteins and oligodendrocyte maturation are sensi-
tive to changes in lamin B1 abundance. Indeed, the effects
of lamin B1 overexpression on gene transcription were
demonstrated by the repression of myelin-specific genes
[76] and the activation of GFAP transcription in oligo-
dendroglial cell lines [26]. Lamin B1 is associated with an
oxidative stress pathway transcriptional factor, octamer
transcription factor 1 (Oct-1), in normal mouse fibroblasts
[77]. Fibroblast cells lacking full-length lamin B1 are
vulnerable to oxidative stress similar to what is found in
Oct-1 knockout cells. In fibroblasts cultured from ADLD
patients, Oct-1 was increased at the nuclear periphery with
reduced nucleoplasmic localization under oxidative stress
conditions [78]. However, whether Oct-1 participates in
the regulation of myelin gene expression and other devel-
opmental defects in the CNS require further investigation.
Supporting in vivo findings, in a primary culture system,
transient overexpression of lamin B1 in oligodendrocytes
by lentiviral transduction causes defects in myelin protein
expression and differentiation accompanied by mild nu-
clear envelope growth/distortion [26]. Overall, these re-
sults indicate that overexpression of lamin B1 could
disturb the unique gene expression patterns in individual
CNS cell types and that these phenotypes would only
appear in certain cell types that are vulnerable to tran-
scriptional perturbance during differentiation. These stud-
ies identify a mechanism by which excessive lamin B1
expression can cause oligodendrocyte cell-autonomous
neuropathology in ADLD, and implicate lamin B1 as an
important factor for myelin formation and maintenance.Therefore, identifying upstream regulators of lamin B1
may provide a means of treating de/dysmyelinating disor-
ders such as ADLD.
MiRNA-23 regulates myelination through multiple
targets including LMNB1
Recently, miRNAs are implicated to regulate a large num-
ber of developmental processes and diseases through fine-
tuning biological networks [79-84]. Expression levels of
miRNAs in oligodendroglia vary according to their state of
differentiation, indicating a possible role for miRNAs in
regulating oligodendrocyte development [85-88]. Notably,
specific miRNAs regulate various important factors in pro-
genitor stages and during OPC differentiation [87-89]. In
addition, ablation of miRNA cluster (miR-17-92) perturbs
oligodendrocyte proliferation through targeting phos-
phatase and tensin homolog on chromosome 10 (PTEN)
[86]. Moreover, disruption of miRNA biogenesis by Dicer
ablation in oligodendroglia at post-developmental stages
results in a neurodegenerative phenotype including demye-
lination, inflammation, and axon loss [90], suggesting that
miRNAs are also important for myelin maintenance at
later developmental stages. Therefore, expression of miR-
NAs at different stages is thought to promote differenti-
ation by antagonizing suppressive factors in progenitors
and/or to keep oligodendrocytes at a mature stage for
myelin maintenance.
As excessive lamin B1 expression appears to be the sole
cause of ADLD, understanding its regulation may provide
insight into potential treatment methods. To deter-
mine whether lamin B1 can be regulated by miRNAs, sev-
eral miRNAs predicted to target LMNB1 were screened
(TargetScan: http://www.targetscan.org/vert_42/). miRNA-
23 (miR-23) is among the most abundant miRNAs in oligo-
dendrocytes [85,86] and is able to counteract the expression
of Lmnb1 [26,57]. In the presence of excess miR-23
in cell culture, a greater proportion of cells express mature
markers of oligodendrocytes that are accompanied by
multipolar morphological appearance and increased levels
of mature myelin proteins, indicating that miR-23 can
enhance differentiation. In contrast, excessive lamin B1
leads to defective differentiation of oligodendrocytes.
Importantly, the adverse effect of lamin B1 on oligo-
dendrocyte cells can be abrogated by miR-23 as a negative
regulator of lamin B1 [26]. Consistent with these observa-
tions, the developmental expression pattern of miR-23
in vivo is reciprocal to that of the lamin B1 [26,91].
The in vivo effects of miR-23 on oligodendrocyte dif-
ferentiation and myelin formation in the CNS were vali-
dated by transgenic mice overexpressing mmu-miR-23a
driven by an oligodendrocyte specific promoter [2’, 3’-cyclic
ucleotide 3’-phophodiesterase (Cnp)] [91]. These mice
exhibit increased myelin thickness, providing in vivo
evidence that miR-23a enhances myelin synthesis [91].
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for CNS myelination, RNA-Seq approach was applied to
examine oligodendrocytes derived from bothmiR-23a trans-
genic mice and control littermates. PTEN was identified as a
potential target and further characterization confirmed that
the PTEN/PI3K/Akt/mTOR pathway is modulated by
miR-23a (Figure 1). Interestingly, a long non-coding RNA
(lncRNA) neighboring PTEN, 2700046G09Rik, was identi-
fied in the same study as another miR-23a target and
modulates PTEN itself in a miR-23a dependent manner.
These data implicate a novel role for miR-23a in the co-
ordination of proteins and non-coding RNAs for generat-
ing and maintaining healthy myelin [91]. lncRNAs have
recently been shown to function as transcriptional and
post-transcriptional regulators of gene expression, such as
through modulation of chromatin modifications, or tran-
scriptional interference by antisense transcription [83,92].
miR-23a upregulates 2700046G09Rik transcription, and
2700046G09Rik in turn lengthens the half-life of miR-23a,
thus potentiating its repressive effects. 2700046G09Rik
can also target its neighboring gene PTEN and lead to a
reduction in PTEN levels. Therefore, repressive effects on
PTEN can either occur with miR-23a alone or in coordin-
ation with 2700046G09Rik. In addition, 2700046G09RikFigure 1 Model for the mechanism of miR-23a in regulating myelinat
B1 in oligodendroglia. Lamin B1 overexpression reduces the occupancy of
causes mislocalization of myelin proteins. 2700046G09Rik interacts with and
alters miR-23a sub-cellular localization, which further enhances repressive e
to AKT activation which then results in myelination. miR-23a represses lamimay aid in the cellular re-compartmentation of miR-23a
into P-bodies, which could also contribute to the regula-
tion of PTEN levels, suggesting that interplay of miR-23a
and 2700046G09Rik infers additional molecular regulation
of mRNA decay [91].
2700046G09Rik is expressed higher in oligodendrocytes
under differentiation conditions than OPCs or astrocytes.
The presence of 2700046G09Rik in oligodendroglia poten-
tiates and signals the activation of the miR-23a-PTEN/
Akt-mTOR cascades in the correct developmental stage,
thus regulating the expression of myelin genes in oligo-
dendrocytes. In addition, two important transcription fac-
tors (YY1 and Nkx2.2) for oligodendroglia [10,11,93] act
on the promoter of 2700046G09Rik, leading to its transac-
tivation during oligodendrocyte development. These find-
ings are consistent with the emerging notion that dynamic
changes of lncRNAs are important for glia differentiation
[94]. Intriguingly, YY1 occupancy at PLP promoter is re-
duced in the LMNB1BAC mice as described earlier [76].
All in all, these findings further highlight the complexity
of oligodendrocyte/myelin regulatory pathways, as dem-
onstrated by the coordination of transcriptional (tran-
scription factors) and post-transcriptional (miRNA and
lncRNA) mechanisms.ion. MiR-23a enhances 2700046G09Rik and represses PTEN and lamin
YY1 on Plp promoter, decreases transcription of myelin genes, and
stabilizes miR-23a. In addition, 2700046G09Rik re-compartments and
ffects of miR-23a on PTEN. Less PTEN in antagonizing PI3K activity leads
n B1 leading to increased myelination.
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Taken together, in vitro and in vivo investigations of
ADLD have established the importance of nuclear lamins,
miRNA, and ncRNA in oligodendroglial development,
and provide potential therapeutic approaches for myelin
diseases. For example, miR-23a may ameliorate reduced
levels of oligodendrocyte- and myelin-specific proteins in
ADLD. In addition, miR-23 can also enhance oligodendro-
cyte development through other lamin B1 independent
pathways such as PTEN/Akt/mTOR. Genetic interaction
studies using mouse models in the future will further
reveal lamin B1 dependent and independent effects of
miR-23a, and thus determine the possibility of developing
non-coding RNAs as potential therapeutic intervention as
well. Although ADLD is a rare disease, it has provided us
with new knowledge on nuclear events underlying myelin
maintenance and events leading to premature myelin
breakdown [76]. Understanding the function of lamins in
the context of lamin-binding-chromatin organization will
also unveil novel mechanisms that mediate myelin dis-
eases, aging process, and other biological functions.
To date, the duplication of LMNB1 is the only disease
that links nuclear structure to myelin formation in the
CNS [18]. Interestingly, duplication of PLP1 is one of
the most common causes of demyelination in Pelizaeus-
Merzbacher disease [95,96]. Overexpression of the com-
mon myelin protein, PLP, causes endoplasmic reticulum
stress, leading to oligodendrocyte demise [97]. It will be
intriguing to investigate threshold effect of gene tran-
scription and translation on myelin formation and other
biological mechanisms where gene and protein expres-
sion homeostasis are critical. Likewise, identification of
upstream enhancer/repressor elements that can modulate
miRNA expression and additional downstream effectors
of lamin B1 and miR-23 may provide novel insights
into the mechanisms of oligodendrocyte development, mye-
lin formation, and maintenance. The LMNB1BAC mouse
model overexpressing lamin B1, mimicking human ADLD,
will be a critical resource for further investigations in vivo,
because while increased lamin B1 expression in neurons
or glia causes lethality in Drosophila [18], the striking
similarities between human and murine oligodendro-
cytes may hasten investigations toward clinical devel-
opment. Growing understanding of human-relevant
pathways critical for myelin regulation will provide novel
screening targets for the treatment of ADLD and other
myelin-based disorders.
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